Cytotoxicity Effect of Shigella flexneri Fraction on Breast Cancer Cell as a New Compound for Cancer Therapy
الموضوعات :
Mehdai Gudarzi
1
(Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR, Iran|Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR, Iran)
Neda Soleimani
2
(Department of Microbiology and Microbial Biotechnology, Faculty of life science and Technology, Shahid Beheshti University, Tehran, Iran)
Mahru Seyyed jafari olia
3
(Department of Microbiology, Faculty of Biological Sciences, Islamic Azad University, Tehran North Branch, Tehran,Iran)
الکلمات المفتاحية: breast cancer, cell death, Shigella, cell viability,
ملخص المقالة :
Breast cancer is a major cause of death among women worldwide. Accordingly, conventional medical treatments using high levels of cytotoxic drugs have some side effects for patients. Different secondary metabolites and enzymes from Shigella are considered in this case. This research aimed to study the effect of Shigella flexneri lysate on the induction of cell death in breast cancer cell line. For this purpose, Shigella lysate was prepared at different concentrations. 4T1 breast cancer cells were treated with different concentrations of bacterial lysate and sediment. The cell death was evaluated by PI color and cell viability was also measured by MTT assay. Analysis of bacterial lysate (IC50 250 μg/ml) for 24 hours has shown the cytotoxic effect on 4T1 breast cancer cells. Moreover, the sediment of bacteria (IC50 500 μg /ml) for 24 hours has shown a cytotoxic effect on 4T1 breast cancer cells. The cell death was confirmed using PI staining. Additionally, the bacterial lysate has shown a direct toxic effect on breast cancer cells. This protein may be used as a new therapy for cancer in future.
1. Bennish M.L., 1991. Potentially lethal complications of shigellosis. Rev Infect Dis. 13, S319-324.
2. Davoli A., Hocevar B.A., Brown T.L., 2010. Progression and treatment of HER2- positive breast cancer. Cancer Chemother Pharmacol. 65(4), 611–23.
3. Agus D.B., Bunn P.A., Franklin W., Garcia M., Ozols R.F., 2000. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 27(6), 53–63.
4. Harirchi I., Kolahdoozan S., Karbakhsh M., Chegini N., Mohseni S.M., Montazeri A., Momtahen A.J., Kashefi A., Ebrahimi M., 2011. Twenty years of breast cancer in Iran: down staging without a formal screening program. Ann Oncol. 22, 93-97.
5. Singh P., Raj R., Kumar V., Mahjan M.P., Bedi P.M.S., Kaur T., 2012. 1, 2, 3-Triazole tethered b-lactam-chalcone bifunctional hybrids: synthesis and anticancer evaluation. Eur J Med Chem. 47, 594-600.
6. Daneshmandi S., Hajimoradi M., Soleimani N., Sattari M. 2011. Modulatory effect of Acetobacter xylinum cellulose on peritoneal macrophages. Immunopharmacology and immunotoxicology. 33(1), 164-168.
7. Yousofi A., Daneshmandi S., Soleimani N., Bagheri K., Karimi M.H., 2012. Immunomodulatory effect of Parsley (Petroselinum crispum) essential oil on immune cells: mitogen-activated spleenocytes and peritoneal macrophages Immunopharmacology and immunotoxicology. 34(2), 303-308.
8. Soleimani N., Daneshmandi S., Sattari M., Pourfathollah A.A., 2011. Immuno-modulatory and anti-tumor effects of cuminum cyminum essential oil. Arak Medical University Journal. 13(4), 22-29.
9. Soleimani N., Mohabati Mobarez A., Teymournejad O., Borhani K., 2014. Cytotoxicity Effect of Recombinant Outer Membrane Inflammatory Protein (oipA) of Helicobacter pylori on a Breast Cancer Cell line. Modares Journal of Medical Sciences: Pathobiology. 17(3), 57-66
10. Soleimani N., Tavakoli-Yaraki M., Farhangi B., 2016. Preparation and Evaluation indirect anticancer activity of D-glucosamine Nanoparticles on Metastatic cancer Model in vivo. Nanomed Res J. 1(1) 15-23.
11. Soleimani N., Mohabati-Mobarez A., 2015. Investigation of the effect of recombinant Neutrophil activating protein (Hp-NapA) of helicobacter pylori on proliferation and viability by peritoneal macrophage from BALB/c mice. Arak Medical University Journal (AMUJ). 18, 43-50.
12. farhangi B., dehghan M.J., soleimani N., salehi Z., 2014. The survey of cytotoxic effect of dendrosomal nano curcumin on 4T1 metastatic model of breast cancer. Police Medicine. 3(3), 183-192
13. Soleimani N., Mohabati-Mobarez A., Tavakoli-Yaraki M., Farhangi B., 2016. Evaluation of nitric oxide production and proliferation activity of recombinant Bacterioferritin of Helicobacter pylori on macrophages. Microbial Pathogenesis. (100), 149-153.
14. Maeda S., 2009. Helicobacter pylori virulence factors except CagA. Nippon Rinsho, 67(12), 2251-6.
15. Hirayama T, Wada A, Yahiro K, Kimura M, Kimura T, 2002. Helicobacter pylori vacuolating cytotoxin, VacA. Jpn J Infect Dis. 55(1), 1-5.
16. Handa O., Naito Y., Yoshikawa T., 2007. CagA protein of Helicobacter pylori: a hijacker of gastric epithelial cell signaling. Biochem Pharmacol. 73(11), 1697-702.
17. Soleimani N., Mohabati-Mobarez A., Atyabi F., Hasan-Saraf Z., Haghighi M., 2014. Preparation of chitosan nanoparticles carrying recombinant helicobacter pylori neutrophil-activating protein. J Mazandaran Univ Med Sci. 23(2), 134-144
18. Galmbacher K., Heisig M., Hotz C., Wischhusen J., Galmiche A., Bergmann B., Gentschev I., Goebel W., Rapp UR., Fensterle J. 2010. Shigella mediated depletion of macrophages in a murine breast cancer model is associated with tumor regression. PLoS One. 5(3), 9572-86.
19. Engedal N., Skotland T., Torgersen M.L., Sandvig K., 2011. Shiga toxin and its use in targeted cancer therapy and imaging. Microb Biotechnol. 4(1), 32-46.
20. Hakomori S., Zhang Y., 1997. Glycosphingolipid antigens and cancer therapy. Chem Biol. 4, 97–104.
21. Sizemore D.R., Branstrom A.A., Sadoff J.C., 1995. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science. 270(5234), 299-302.
22. Suarez N., Ferrara F., Rial A., Dee V., Chabalgoity J.A., 2020. Bacterial Lysates as Immunotherapies for Respiratory Infections: Methods of Preparation. Front Bioeng Biotechnol. 8(545), 1-8.
